HUE029911T2 - Az atorvastatin kalcium oxidatív bomlásának termékei - Google Patents

Az atorvastatin kalcium oxidatív bomlásának termékei Download PDF

Info

Publication number
HUE029911T2
HUE029911T2 HUE05760907A HUE05760907A HUE029911T2 HU E029911 T2 HUE029911 T2 HU E029911T2 HU E05760907 A HUE05760907 A HU E05760907A HU E05760907 A HUE05760907 A HU E05760907A HU E029911 T2 HUE029911 T2 HU E029911T2
Authority
HU
Hungary
Prior art keywords
ppm
atorvastatin
atv
hydroxy
phenyl
Prior art date
Application number
HUE05760907A
Other languages
English (en)
Inventor
Rok Grahek
Darko Kocjan
Andrej Bastarda
Andrej Kocijan
Matjaz Kracun
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE029911(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of HUE029911T2 publication Critical patent/HUE029911T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)

Claims (4)

  1. Ä mwmmMMûkm. ôxjdaîiy1^Âsàô|(i:%f»iék#i; di oxa-Smaxa-aklapropajal Inden- 3 ~i i]-3-(R)»hi droxí-v aj sav, :2,. 4^p*in#ï*ÎeniI)*2s4"dihidroxi*2-Ie)prppil*S~ten{R3 «é'íiioxáMcikic^S.l <bjbéxln-l * karbonsav fenilamid, 3. 44 lh44-dtior”fenil)-64nIroxl:vö-izopröpiMa~feniiÄ dioxa- Sa-aza-ej feiopropa|aj Inden~3vll| ~|~(R)*B|drpxi *va|;s^.
  2. 4, Eljárás valamely, ax alábbiak közül választott vegyület előállítására: 4-!6-(4~!:lnot~ fenti) ·6··ΗκΙ··Γθχι·· I boxoptopil-ba-tcnil·' I a- tend kar bamotl-hexâhidro-1 ;2-dioxa-5a-aza-eiklo~ prepa fa] ioden- 3 - I I] * 3 ~ (RVhkbo\i~w!vn, ti oot-lem!) 4~dmíd,ov ? vopsopd ^ ,eon - 3^-diox#loiMö[3J.Ö]hexární*karbonsav femlamid vagy 4-j. 1 tx^-íluor-feniI)-6-hiároxiS- ixepropil4:axjbtiiE6a-ieniikafbamoiEhexaMdro-T,2-dh^ p)-hi.dtoxEva|sav, azzal jellemezve, hogy egy szilárd atorvastáiin :sót levegőn vagy oxigén-atmoszférábáík 40-40 *€*ós enieiti bintérsdklnten oxidáEmk:. 3. á l. igénypont szerinti eljárás, ahol a szilárd atorvastatin sót az alábbi csoportból választjuk: atorvastatin kalcium, nátrium, kálium, magnézium és ammonium, 6. A 4. vagy 5. Igénypont szerinti eljárás, ahol az atorvastatin só oxidációját az atorvastatin se vizáéi és/vagy egy szerves oldószerre! étvágy oldószerek keverékével készített: oldatában végezzük, ahol az oldószereket az alábbi csoportból választjuk: aeeíoniirtk metanol, etanoL propanol, diklóometan vagy metslen-kiund, hidrogen-peroxid kozzánuusa mel-lett, vagy levegőnek vagy oxigénnek az oldaton történd átáramoltatásával 40-90 °C-on. f. Eljárás valamely, az alábbiak közül választott vegyület előállítására: 4-(6-(4-flner-lenih-6'hidroxi' 1 b-izopropil-óa-fenil-1 a-feniíkarbarooil-hexahídro- 1,2~dioxa-5a-aza-cik)os propaía]índ.ea-3-iiIj-3-(R:Ebidroxi-vr|sa:V, 4-|4-flnor-ieniI)-2,4«dintdroxn2-iZopropib5-lctriE 3,6-dioxalhciki.Q[3.1,01 hexán-1-karbonsav fenilamid vagy 4-|lb-(4-ÍIuor-íénií)-6-rüdíexi~6-ig;opïXï:piI~là~iîîitl-ë^ieniikarbâfôeI!~hexâhidro:4 J-diöxa-5á"a2a~clMteprohkfá]índen''3-il]~3'' P>hidroxl:o/ajMV5 -aasgál jellemezve,. hegy egy atörvamatln ső oldata napfénynek vagy mesterséges mpféïïymk »Ä ki 8, A 7. igényimni szerinti eljárás, ahol a szilárd ator vastartó sót az alábbi csoportból válásaink; atorvastatin kalcium, nátrium, kálium, mapézinm és ammonium- f, A 4*S. igénypőntök bánnelyike szerinti ef írása amely továbbá egy vagy több izolálást lépést is taríalnmz. 10. A 9. igénypont szerinti eljárás, ahol az izolálás! lépést az alábbiak küzdi választjuk: preparatiy normál fázisú és fordított fázisú kromaiogmija.
  3. 11. A if), igénypont szerinti eljárás. ahol a preparatlv normái Má kromatográita aurán m alábbi csoportból választott szilikagék vagy szilika-alapn kitbtf fázisokat alkalmazzuk:: atnlnopmpllo cianopropib, diót- és niiroiénik 1:3, A 11. igénypont szerinti: eljárás, ahol a prepafativ normál bíztad kromaiogfáíla során a mozgó fázis egy poláros módosltö alkoholból és: egy nem: poláros oldószerből álló keveréket tartalmaz, ahol az aikehö! metánok: etanok propanol vagy aeetooltrlk és a nent-poláros oldd“· szer hexán, biklórmetln, metibeiklökexán: vagy ezek bármely konthiMoiip lehet. 13. A !§, igénypont szerinti épráa, .fhol a preparaíiv fordítóit fázisú kromatógrlia sot'án sziikagéíhez kötödokiadeoibszüám vagy oktüsziíáni alkalmazunk,
  4. 14. A ÍJ, igénypont szerion eljárás,: ahol pfepaTätlv íbrditott fázisú kromálográiM során a mozgóiazls víz, egy szerves vagy szervetlen puffer és egy vagy több szerves módosító anyag keverékét tartalmazza, ahol a széfvös módosító anyag valamely alkohöi'^0y:ädeidölMl:IÄt
HUE05760907A 2004-07-16 2005-07-15 Az atorvastatin kalcium oxidatív bomlásának termékei HUE029911T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400209 2004-07-16
SI200400348 2004-12-24

Publications (1)

Publication Number Publication Date
HUE029911T2 true HUE029911T2 (hu) 2017-04-28

Family

ID=35457712

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05760907A HUE029911T2 (hu) 2004-07-16 2005-07-15 Az atorvastatin kalcium oxidatív bomlásának termékei

Country Status (14)

Country Link
US (4) US8044086B2 (hu)
EP (1) EP1771455B1 (hu)
JP (1) JP5000502B2 (hu)
CN (1) CN1997651B (hu)
AU (1) AU2005263550C1 (hu)
BR (1) BRPI0513396A (hu)
CA (2) CA2573969C (hu)
ES (1) ES2586561T3 (hu)
HU (1) HUE029911T2 (hu)
MX (1) MX2007000582A (hu)
PL (1) PL1771455T3 (hu)
RU (1) RU2412191C2 (hu)
SI (1) SI1771455T1 (hu)
WO (1) WO2006008091A2 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321132B (en) 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IS8607A (is) * 2007-02-09 2008-08-10 Actavis Group Hf. Stöðugar atorvastatin samsetningar
WO2011077843A1 (ja) * 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
CN110646550B (zh) * 2018-06-26 2022-12-02 北京伟林恒昌医药科技有限公司 一种阿托伐他汀钙中有关物质的检测方法
CN115754025A (zh) * 2021-09-02 2023-03-07 上虞京新药业有限公司 一种匹伐他汀钙中基因毒性杂质gt1的检测方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3114497A (en) * 1962-05-18 1963-12-17 Kugler Emanuel Drawstring bag
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
ES2167587T3 (es) * 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
KR100681366B1 (ko) * 1997-12-19 2007-02-12 워너-램버트 익스포트 리미티드 1,3-디올의 합성방법
IN191236B (hu) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
JP2003523948A (ja) 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
WO2001037876A2 (en) 1999-11-24 2001-05-31 Bayer Aktiengesellschaft Methods of ameliorating abnormal bone states
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
MXPA02004078A (es) * 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
WO2001044181A1 (en) * 1999-12-17 2001-06-21 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
DE60020732T2 (de) * 1999-12-20 2006-05-11 Kerkhof, Nicholas J., Rio Vista Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
US20030018040A1 (en) 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
AU2002232891B2 (en) * 2000-11-16 2006-12-14 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) * 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
WO2003011826A1 (en) 2001-07-30 2003-02-13 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
PE20030324A1 (es) 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
KR20090045420A (ko) * 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
EP1727795B1 (en) * 2004-03-17 2012-02-15 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form

Also Published As

Publication number Publication date
US20100219063A1 (en) 2010-09-02
WO2006008091A2 (en) 2006-01-26
AU2005263550C1 (en) 2013-01-17
ES2586561T3 (es) 2016-10-17
US8044086B2 (en) 2011-10-25
US9453030B2 (en) 2016-09-27
AU2005263550A1 (en) 2006-01-26
CA2573969C (en) 2014-02-04
CN1997651B (zh) 2012-06-06
US20070208071A1 (en) 2007-09-06
RU2007105689A (ru) 2008-08-27
BRPI0513396A (pt) 2008-05-06
SI1771455T1 (sl) 2016-09-30
JP5000502B2 (ja) 2012-08-15
WO2006008091A3 (en) 2006-09-08
PL1771455T3 (pl) 2016-11-30
MX2007000582A (es) 2007-03-30
EP1771455B1 (en) 2016-05-11
AU2005263550B2 (en) 2011-11-03
US20150105551A1 (en) 2015-04-16
US20100056605A1 (en) 2010-03-04
CA2573969A1 (en) 2006-01-26
EP1771455A2 (en) 2007-04-11
JP2008506655A (ja) 2008-03-06
CA2833770A1 (en) 2006-01-26
RU2412191C2 (ru) 2011-02-20
CN1997651A (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
US9453030B2 (en) Oxidative degradation products of atrovastatin calcium
JP5765739B2 (ja) ロスバスタチンラクトールの薬物としての使用
IL184035A (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
JP2017519839A (ja) プリドピジンの類似体、それらの製造および使用
KR100881103B1 (ko) 실질적으로 불순물을 함유하지 않는 아토르바스타틴 칼슘의형태를 제조하는 방법
RU2752568C2 (ru) Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм
US20110112165A1 (en) Atorvastatin-aliskiren
IE75695B1 (en) 3-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-3H-imidazo [4,5-b]-pyridin-2-amine 2-hydroxy-1,2,3-propanetricarboxylate
KR20160117843A (ko) 결정형 및 이의 제조방법
KR20110128193A (ko) 의약제로서의 아토르바스타틴 락톨의 용도
EP4105215A1 (en) Co-crystal of apixaban with a carboxylic acid
US20160039871A1 (en) Novel forms of telaprevir
EP3656767A1 (en) Beraprost-314d monohydrate crystals and methods for preparation thereof